3. Nanopharmacotherapy
Area 3 comprehends the
following research lines:
A.- Nanostructured Systems for controlled drug release. Nanocapsules.
B.- Nanoestructured systems interaction with biological strucures.
C.- Bioavailability, toxicity and therapeutic efficiency of nanostructured systems.
D.- Non-viral vectors. Gene therapy. Pharmacogenomics and nutrigenomics.
E.- Molecular internalisation. Molecular marking. Detoxification.
A.- Nanostructured Systems for controlled drug release. Nanocapsules.
B.- Nanoestructured systems interaction with biological strucures.
C.- Bioavailability, toxicity and therapeutic efficiency of nanostructured systems.
D.- Non-viral vectors. Gene therapy. Pharmacogenomics and nutrigenomics.
E.- Molecular internalisation. Molecular marking. Detoxification.
This area aims to the development of nanostructures systems for controlled
drug release and to the improvement of drug therapeutic efficiency when
administered on target body. A reduction of toxicity on healthy tissues
is also sought.
Area 3 is composed of the folloeing resarch groups:
- Drug development in nanostructured systems
- Design and evaluation of drug response within nanostructured and self-organised drug systems
- Colloids
- Combinatorial hemistry for the discovery of new drugs